Correlation Between Neurobo Pharmaceuticals and Eliem Therapeutics
Can any of the company-specific risk be diversified away by investing in both Neurobo Pharmaceuticals and Eliem Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Neurobo Pharmaceuticals and Eliem Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Neurobo Pharmaceuticals and Eliem Therapeutics, you can compare the effects of market volatilities on Neurobo Pharmaceuticals and Eliem Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Neurobo Pharmaceuticals with a short position of Eliem Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Neurobo Pharmaceuticals and Eliem Therapeutics.
Diversification Opportunities for Neurobo Pharmaceuticals and Eliem Therapeutics
0.83 | Correlation Coefficient |
Very poor diversification
The 3 months correlation between Neurobo and Eliem is 0.83. Overlapping area represents the amount of risk that can be diversified away by holding Neurobo Pharmaceuticals and Eliem Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Eliem Therapeutics and Neurobo Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Neurobo Pharmaceuticals are associated (or correlated) with Eliem Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Eliem Therapeutics has no effect on the direction of Neurobo Pharmaceuticals i.e., Neurobo Pharmaceuticals and Eliem Therapeutics go up and down completely randomly.
Pair Corralation between Neurobo Pharmaceuticals and Eliem Therapeutics
Given the investment horizon of 90 days Neurobo Pharmaceuticals is expected to under-perform the Eliem Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Neurobo Pharmaceuticals is 1.06 times less risky than Eliem Therapeutics. The stock trades about -0.02 of its potential returns per unit of risk. The Eliem Therapeutics is currently generating about 0.04 of returns per unit of risk over similar time horizon. If you would invest 252.00 in Eliem Therapeutics on August 27, 2024 and sell it today you would earn a total of 48.00 from holding Eliem Therapeutics or generate 19.05% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Strong |
| Accuracy | 99.8% |
| Values | Daily Returns |
Neurobo Pharmaceuticals vs. Eliem Therapeutics
Performance |
| Timeline |
| Neurobo Pharmaceuticals |
| Eliem Therapeutics |
Neurobo Pharmaceuticals and Eliem Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Neurobo Pharmaceuticals and Eliem Therapeutics
The main advantage of trading using opposite Neurobo Pharmaceuticals and Eliem Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Neurobo Pharmaceuticals position performs unexpectedly, Eliem Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eliem Therapeutics will offset losses from the drop in Eliem Therapeutics' long position.| Neurobo Pharmaceuticals vs. Allarity Therapeutics | Neurobo Pharmaceuticals vs. Virax Biolabs Group | Neurobo Pharmaceuticals vs. Quoin Pharmaceuticals Ltd | Neurobo Pharmaceuticals vs. Biodexa Pharmaceticals |
| Eliem Therapeutics vs. Pmv Pharmaceuticals | Eliem Therapeutics vs. MediciNova | Eliem Therapeutics vs. Pharvaris BV | Eliem Therapeutics vs. PepGen |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Other Complementary Tools
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing |